GlassScriptPhysician profile
Sean D Fine
NPI 1114210267
$54,972.75
in general payments reported to CMS, 2019-2025
13 companies · $632 in 2025
The $632 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $8,721 · 2021: $6,085 · 2022: $7,647 · 2023: $10K · 2024: $2,807 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,485 · Honoraria: $3,500 · Food and Beverage: $2,111 · Travel and Lodging: $1,622 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,485.00 |
| Honoraria | $3,500.00 |
| Food and Beverage | $2,111.42 |
| Travel and Lodging | $1,621.78 |
| Education | $100.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,748.55 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $12,988.29 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $11,924.28 | 2021-2023 | |
| Pharmacosmos Therapeutics INC. | $5,300.19 | 2023 | Monoferric |
| Janssen Biotech, INC. | $3,373.49 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $2,388.22 | 2019-2025 | Entyvio |
| Celgene Corporation | $1,811.60 | 2019-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $121.60 | 2025 | Zenpep |
| Olympus America INC. | $106.24 | 2019 | |
| Braintree Laboratories, INC. | $85.07 | 2019-2021 | |
| Genzyme Corporation | $80.75 | 2025 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.77 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.